Here's your roundup of energy innovation news coming out of Houston. Photo via Getty Images

Houston's energy innovation ecosystem has seen a busy spring season, with startup accelerator cohorts announced, expanded corporate partnerships, and recent funding raised.

In this roundup of short stories within Houston energy innovation, a startup enters into a strategic partnership, Greentown Labs announces a new accelerator, and more.

Syzygy taps global company to lead scaling for tech development 

Syzygy has brought on a new partner that's key to its future growth and tech production. Photo via Emerson

Houston-based Syzygy Plasmonics, which has developed a light-based catalyst reactor technology that originated out of Rice University, has selected global technology and software company Emerson (NYSE: EMR) to automate electrification of chemical production processes.

The reactor technology uses light instead of thermal energy for chemical manufacturing. The all-electric production method has the opportunity to replace fossil fuel-based combustion, making energy generation more sustainable. Syzygy estimates, according to the news release, that its reactor systems could eliminate 1 gigaton of CO2 emissions by 2040.

“We are excited to advance this opportunity with Emerson not only for its automation technologies and software but also its sustainability leadership and domain expertise in chemical engineering, electrification and hydrogen production,” says Syzygy CEO Trevor Best in the release. “As we expand beyond traditional paradigms of reactor technology and launch a new way to electrify chemical manufacturing, we wanted a technology partner who can help us scale our technology efficiently, safely and reliably.”

Emerson will provide its suite of hardware, software, and services for the Syzygy modular reactors.

"Emerson is excited to collaborate with Syzygy Plasmonics on such promising technology that could have a significant impact on industries that are some of the most challenging to decarbonize," says Peter Zornio, CTO at Emerson. “This aligns with Emerson’s culture of innovation that takes on our customers’ biggest challenges.”

Greentown Labs announces applications opening for Shell accelerator

Shell is seeking energy tech companies. Photo via greentownlabs.com

Greentown Labs, a climatetech incubator co-located in Houston and Boston, has teamed up with Shell for a Greentown Go program, geared at accelerating startup-corporate partnerships, to focus on technologies for carbon utilization, storage, and traceability.

Greentown Go Make 2023 zeroing in on alternative carbon feedstocks for carbon-intensive commodities; biogenic and nature-based solutions; and solutions for carbon storage and traceability, according to a news release.

Applications are open now, and the selected startups will have access to mentorship from Shell and Greentown's networks, desk space and membership within Greentown, $15,000 in non-dilutive grant funding, and educational workshops throughout the duration of the six-month program.

“Greentown Go brings together groundbreaking climatetech startups and the corporations that can help commercialize and scale their technologies,” says Kevin T. Taylor, interim CEO and CFO at Greentown Labs, in a news release. “Every Greentown Go program aims to drive climate impact and accelerate the energy transition. We look forward to working with Shell, a long-time Greentown partner, on this important program and supporting the latest innovations in carbon utilization, storage, and traceability.”

The program will help support Shell’s strategy through the development and scaling of technologies for carbon utilization, storage, and traceability across chemicals, carbon fuels, and more.

“Collaboration to accelerate technology development is critical to developing the energy solutions we need for a low-carbon energy future, and I am excited to see what novel technologies arise from startups participating in the Greentown Go Make 2023 program,” says Ed Holgate, commercial partnerships manager at Shell.

Chevron Technology Ventures adds Canadian startup to its Catalyst Program

Motive.io ia using AI to optimize workforce training. Photo via Motive.io

Chevron Technology Ventures announced the addition of Vancouver-based Motive.io, which provides immersive training solutions that leverage virtual and augmented reality technologies, to its Catalyst program. The program seeks out and helps to grow breakthrough technologies and solutions that have the potential to disrupt the energy industry.

"We are honored and thrilled to be selected as part of Chevron Technology Ventures' Catalyst program," says Ryan Chapman, CEO of Motive.io, in a news release. "Selection for this program represents a tremendous opportunity for Motive.io to collaborate with Chevron Technology Ventures as we continue to advance our cutting-edge immersive training solutions for the energy sector."

Motive.io's technology, called the XR Management System, "aims to revolutionize how companies train their employees by providing realistic and interactive simulations that allow learners to practice their skills in a safe and controlled environment," according to a news release.

Chevron has brought on two startups as a part of its Catalyst Program that helps accelerate and mature energy tech companies. Photo via Getty Images

Chevron's Houston-based venture group taps two companies for its startup-focused program

energy tech

Chevron's corporate venture arm that invests into energy tech innovation and supports startups within the industry has tapped two companies for its Chevron Technology Ventures Catalyst Program.

Entech Solutions and mIQroTech have both recently been named new partners in the program, which allows the startups support and guidance during growth and acceleration from Chevron and its network.

Norway-based Entech Solutions AS has developed itsSuperstage Pinpoint Stimulation to address high intensity stimulation in increasingly long horizontal wells, according to a press release. The product aims to improve production performance and lower costs.

"Collaboration with Chevron will allow us to demonstrate Superstage efficiencies in a variety of basins worldwide," says Anthony Kent, co-inventor of Superstage and Entech's General Manager for North America, in the release.

"Working with a leading global operator gives us access to expertise needed to standardize this robust and versatile hardware technology," he continues.

Meanwhile, Tampa, Florida-based mIQroTech is addressing pipeline leak concerns within the energy industry by using artificial intelligence and internet of things. The startup joined the Catalyst Program in July.

"Our goal is to deliver a transformative change to the global oil and gas industry," says founder and chief executive officer, Meade Lewis, in a press release.

"Better data, analytics, and intelligence will add efficiencies to pipeline operations and empower more informed and faster decision-making. We appreciate that Chevron recognizes our potential to deliver solutions to enable safer delivery of oil and gas," Lewis continues.

The company, which has received investments from Plug and Play, Ocean Capital, Republic, and Harvard Business School Alumni Angels, and more, will focus on growing its team and customer base.

Chevron also recently contributed to Houston-based ThoughtTrace's $10 million series B round in May and signed on as a partner for the Houston expansion of cleantech accelerator Greentown Labs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”